FibroGen (FGEN) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
FibroGen Reports Second Quarter 2022 Financial Results
August 8, 2022 4:01 PM EDTCompleted enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant roxadustat volume growth in China
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the companys recent developments.
We continue making excellent progress with pamrevlumab across all our high value indications and... More
